- Trial Phase
- Phase 3 / Filed BLA
- Time to Market
- LVAD/heart failure BLA now under FDA review with modular review requested — no PDUFA date set yet (potentially 2027 if accepted). CLBP indication likely 2028 at earliest (topline mid-2027, BLA Q3 2027, FDA action 2028).
- Why 6/10
- The nearest hard catalyst is the FDA's review of rexlemestrocel-L's BLA in LVAD/end-stage heart failure (filed June 30, 2026, modular review requested). No PDUFA date is set yet, but RMAT designation enables priority review. The CLBP Phase 3 topline readout (mid-2027) is the next major binary. This drug is a major pipeline value driver at a company that also has a commercial product (Ryoncil), so it's not a pure single-asset binary — hence a 6, not an 8+.
Mesoblast just filed a BLA for rexlemestrocel-L in LVAD/heart failure — the next catalyst is FDA acceptance and a PDUFA date. Meanwhile, the much larger CLBP opportunity (7M+ US patients, non-opioid approach) is advancing with Phase 3 enrollment complete and topline due mid-2027. The company already generates real revenue from Ryoncil (~$110-120M FY2026 guidance), de-risking the story vs. pre-revenue biotechs. Monitor (1) FDA's action on the LVAD BLA modular review, (2) CLBP Phase 3 topline in mid-2027, and (3) Ryoncil revenue growth trajectory.
Price Chart
Executive Summary
Rexlemestrocel-L (Revascor) is Mesoblast's lead cell therapy pipeline asset — an off-the-shelf, donor-derived mesenchymal precursor cell treatment for inflammatory and degenerative conditions. It is furthest along for end-stage heart failure (BLA filed June 30, 2026 with modular review) and chronic low back pain (Phase 3 enrollment complete, topline mid-2027). Mesoblast already has an FDA-approved commercial product (Ryoncil, approved Dec 2024) generating meaningful revenue, which de-risks the story versus typical pre-revenue biotechs. The stock has strong analyst support (9 analysts, mostly buy, $35 mean price target vs ~$14.38) and major insider buying. However, the DREAM-HF Phase 3 heart failure trial had mixed results (missed primary endpoint), the LVAD BLA timeline is uncertain, and the largest commercial opportunity (CLBP) won't read out for another ~12 months.
How It Works
A living cell therapy made from donor bone marrow cells. These mesenchymal precursor cells (MPCs) are specially selected and grown in a lab, then injected into patients. Rather than replacing damaged cells, they work by dialing down harmful inflammation and signaling the body to repair tissue — like sending in a crew of cellular firefighters and repairmen. Because the cells come from generic donors (not the patient), they can be manufactured in batches and stored for immediate use as an off-the-shelf treatment.
Trial Status
Rexlemestrocel-L is in Phase 3 trials and/or under regulatory review for four distinct indications. (1) End-stage heart failure with LVAD: BLA filed June 30, 2026 with modular review requested; has RMAT and Orphan Drug designations enabling accelerated/priority review. (2) Chronic low back pain (CLBP): confirmatory 300-patient Phase 3 trial (MSB-DR004) completed enrollment April 2026; topline results expected mid-2027; BLA filing targeted Q3 2027; RMAT designation granted. (3) Ischemic chronic heart failure with inflammation: FDA alignment on BLA requirements reached June 2025; BLA in preparation. (4) Hypoplastic left heart syndrome (HLHS): RMAT, Rare Pediatric Disease & Orphan Drug designations.
The Two-Sided Case
Upcoming Catalysts
- FDA acceptance/review progress on LVAD BLA (modular review requested June 30, 2026)
- Setting of PDUFA date for LVAD BLA
- CLBP Phase 3 topline data (mid-2027)
- BLA filing for CLBP (targeted Q3 2027)
- Potential BLA filing for ischemic heart failure with inflammation
Source Filing
The SecBot filing or press-release report that triggered this drug report:
MESOBLAST LTD 6-K MESO ·Originating report